In New York, Raymond James investment advisors have sent a message on Solazyme: buy, buy, buy. Their analysis claims that the company’s low stock values should be incentive for investors to buy, asserting that the decline in stock is a result of multiple compressions comprising the lack of stories, the delays and troubles by other biofuels companies, and the reports of insider selling. However, they predict that Solazyme is a pre-earnings company: it has a very stable balance sheet and upcoming scaled production capability meaning it will soon be turning large profits.
More background on the story from the Digest
Category: Producer News